The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, ...

Vision Marine Technologies Inc. (NASDAQ:VMAR), a pioneer in electric marine propulsion, today announced that the Company’s board of directors (the “Board”) approved a 10 -for-1 reverse stock split of ...

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste ...

Napo科学顾问委员会 (SAB)成员、转移性乳腺癌患者Kelly Shanahan博士表示，管理救命癌症药物引起的副作用至关重要。据Jaguar总裁兼首席执行官Lisa Conte称，克罗菲尔默在为接受靶向治疗的乳腺癌患者提供持续性腹泻改善方面比安慰剂更有效。

Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified ...

As announced, the analysis of the prespecified subgroup of adult patients with breast cancer from the Company's recently conducted Phase 3 prophylactic OnTarget clinical trial for diarrhea in ...